Mirum outlines $715M to $720M 2026 net product sales guidance while targeting cash flow positive next year (NASDAQ:MIRM)

Mirum Pharmaceuticals reported Q3 revenue growth of $10M-$15M, expecting this trend to continue through 2027. ATEBRIOZ, approved in September, began U.S. launch with positive early feedback. The company anticipates multiple regulatory submissions in 2027. Mirum ended Q3 with $500M in cash and expects R&D expenses to decline to 10% of revenue long-term.

Mirum Pharmaceuticals reported Q3FY26 net product sales of $186M, up 40% YoY. The company raised full-year guidance to $715M-$720M, beating estimates. Livmarli drove growth, with adult PFIC as a key driver. Operating expenses were $245M, with R&D at 50% of revenue. Cash position is ~$500M. The company plans several regulatory milestones and expects cash flow positivity next year.

Mirum Pharmaceuticals, Inc. (MIRM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update – Q3 2026 net product sales of $185.7 million; 2026 net product sales guidance increased to $715 million to $720 million – Received U.S. FDA approval of and launched ATEBR

Mirum Pharmaceuticals reported Q3 2026 net product sales of $185.7M, up 45% YoY for LIVMARLI and 28% for Bile Acid Medicines. The company received FDA approval for ATEBRIOZ and reported positive Phase 3 results for LIVMARLI, ATEBRIOZ, and brelovitug. Mirum raised full-year net product sales guidance and expects multiple regulatory submissions in 2027. Total revenue was $133.0M, with operating expenses at $130.4M.

Mirum Pharmaceuticals will present data on its hepatitis D treatment, brelovitug, at The Liver Meeting 2026, including Phase 3 results and longer-term efficacy in patients with cirrhosis. The company will also share additional analyses on volixibat for primary sclerosing cholangitis (PSC) and new evidence on LIVMARLI (maralixibat) for rare cholestatic liver diseases.

Mirum Pharmaceuticals reported positive Phase II trial data for Atebrioz (zilurgisertib) in paediatric FOP patients. Over 24 weeks, the drug reduced lesion volume and improved joint mobility. Mirum plans to submit an NDA expansion in 2027. The study showed a mean HO lesion volume reduction of 8.09cm³ with zilurgisertib versus a 9.14cm³ increase with placebo.